Unusual movement in Hong Kong stocks | Hoya Pharmaceuticals-B (02256.HK) surged more than 11% after the recent announcement of the results of the ABSK061 combined with ABSK043 treatment for FGFR2-positive advanced GC/GEJC phase II study.
According to the Securities Times APP, China Harmony-B (02256.HK) rose by more than 11%, as of the time of publication, it had increased by 9.08%, reaching 10.21 Hong Kong dollars, with a turnover of 23.6689 million Hong Kong dollars.
Latest
58 m ago
